A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Roferon-A Patient, Information, Instructions - Interferon alfa-2a, Recombinant
Roferon-A Patient, Information, Instructions - Interferon alfa-2a, Recombinant
PATIENT INFORMATION
Patients should be cautioned not to change brands of Interferon without
medical consultation, as a change in dosage may result. Patients should
be informed regarding the potential benefits and risks attendant to the
use of Roferon-A. If home use is determined to be desirable by the physician,
instructions on appropriate use should be given, including review of the
contents of the enclosed Patient Information Sheet. Patients should be
well hydrated, especially during the initial stages of treatment.
Patients should be thoroughly instructed in the importance of proper
disposal procedures and cautioned against reusing syringes and needles.
If home use is prescribed, a puncture-resistant container for the disposal
of used syringes and needles should be supplied to the patient. The full
container should be disposed of according to directions provided by the
physician.
Patients receiving high-dose alfa interferon should be cautioned against
performing tasks that require complete mental alertness such as operating
machinery or driving a motor vehicle. Patients to be treated with Roferon-A
should be informed that depression and suicidal ideation may be side effects
of treatment and should be advised to report these side effects immediately
to the prescribing physician.
top
